International Flavors & Fragrances, Inc. is a creator and manufacturer of products for application in food, beverage, health & biosciences, and scent. The company operates through five business segments: Taste, Food Ingredients, Health & Biosciences, Scent, and, until its divestiture in May 2025, Pharma Solutions. Its Taste segment develops flavor compounds and natural taste solutions for savory products, beverages, sweets, and dairy. The Food Ingredients segment provides natural, artificial, and plant-based specialty food ingredients, including soy and pea proteins, emulsifiers, sweeteners, and natural food protection ingredients. Health & Biosciences produces biotechnology-derived enzymes, food cultures, probiotics, and specialty ingredients for food, non-food, animal nutrition, and grain processing applications. The Scent segment creates fragrance compounds and ingredients for fine fragrances, fabric care, home care, and body care products. The company serves manufacturers of dairy, meat, beverages, snacks, personal care, cleaning products, perfumes, dietary supplements, and animal nutrition products globally. It holds positions in the Food & Beverage, Home & Personal Care, and Health & Wellness markets. The company was founded in 1889 as Pollak & Schwartz, a producer of fruit flavors and oil essences, and later merged with Van Ameringen-Haebler, Inc. It has acquired or partnered with entities including Bush Boake Allen, Laboratoire Monique Remy, Otten Flavors, David Michael & Company, Frutarom, and DuPont Nutrition & Biosciences.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Specialty Chemicals Homepage iff.com
Sector Basic Materials IR page ir.iff.com
Tags
flavor compounds, fragrance ingredients, food enzymes, probiotics, soy protein, animal nutrition, grain processing, natural food preservation, dietary supplements, bioscience solutions, Bush Boake Allen, Laboratoire Monique Remy, Otten Flavors, David Michael & Company, Frutarom, DuPont Nutrition & Biosciences, Living Flower, Solid Phase Micro Extraction, Living Flavor, Pollak & Schwartz, Van Ameringen-Haebler Inc.
Press page iff.com/media/newsroom

Metrics

Valuation  
Market cap $ 20.903B
Market cap (USD) $ 20.903B
P/E -59.21
PEG —
P/BV 1.58
P/S 2.27
P/OCF 18.37
P/FCF 41.72
Dividend yield 1.9%
Turnover / mcap —
Returns  
ROE -2.6%
ROI -1.8%
ROIC -1.4%
Profit margin -3.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 47.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score -36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 10.89B 11.484B 11.479B 12.44B 11.656B 5.084B 5.14B 3.978B 3.399B 3.116B 3.023B 3.089B 2.953B 2.821B 2.788B 2.623B 2.326B 2.389B 2.277B 2.095B 1.993B 2.034B 1.902B 1.809B 1.844B 1.463B
Net profit -359M 247M -2.563B -1.864B 279M 367.372M 460.268M 339.781M 295.665M 405.031M 419.247M 414.543M 353.544M 254.134M 266.866M 263.557M 195.526M 229.628M 247.128M 226.5M 193.066M 196.071M 172.597M 175.944M 116.002M 123.005M
Free cash flow 256M 607M 936M -107M 1.044B 522.304M 462.987M 267.481M 261.783M 408.994M 332.548M 375.208M 273.405M 197.656M 61.733M 208.835M 224.818M 135.218M 248.448M 204.619M 83.727M 225.24M 203.641M 161.529M 129.489M 208.414M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 67.39 84.55 80.97 104.84 150.65 108.84 129.02 134.27 152.61 117.83 119.64 101.36 85.98 66.54 52.42 55.59 41.14 41.93 50.96 48.82 — — — — — —
Price performance 12m -0.2 0.04 -0.23 -0.3 0.38 -0.16 -0.04 -0.12 0.3 -0.02 0.18 0.18 0.29 0.27 -0.06 0.35 -0.02 -0.18 0.04 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 551M 664M 938M 60.8M 929M 1.91B 1.82B 1.73B 1.62B 1.73B
↳ YoY growth +2.4% +20.5% +41.3% -93.5% +1,429.6% +105.1% -4.6% -5.1% -5.9% +6.6%
↳ 5y CAGR +3.1% +5.9% +12.3% -34.2% +11.6% +28.2% +22.3% +13.0% +92.9% +13.2%
Borrowings, current (USD) 259M 6.97M 48.6M 385M 634M 956M 784M 885M 1.41B 1.57B
Borrowings, non-current (USD) 1.07B 1.63B 4.5B 4B 3.78B 10.8B 10.4B 9.19B 7.56B 4.74B
Lease liabilities (USD) — — 0.00 296M 312M 799M 668M 752M 644M 657M
Cash and deposits (USD) 324M 368M 635M 607M 650M 711M 483M 703M 469M 590M
Intangible assets (USD) 366M 416M 3.04B 2.85B 2.73B 10.5B 9.08B 8.36B 6.45B 6.04B
Right-of-use assets (USD) — — 308M 288M 299M 767M 636M 689M 573M 579M
Net debt (borrowings + leases - cash) (USD) 1B 1.27B 3.92B 4.07B 4.08B 11.8B 11.3B 10.1B 9.15B 6.38B
Cash flow detail
Operating cash flow (USD) 535M 391M 438M 699M 714M 1.44B 397M 1.44B 1.07B 850M
Purchases of property, plant and equipment (USD) -126M -129M -170M -236M -192M -393M -504M -503M -463M -594M
Purchases of intangible assets (USD) 0.00 0.00 -3.33M -6.07M 0.00 -4M -2M 0.00 -5M -2M
Change in receivables (cash effect) (USD) -21.5M -68.9M -50M 59.6M -61M -169M -117M 51M -217M -68M
Change in inventories (cash effect) (USD) 15.5M -18.9M -118M -62.1M 17.9M -363M -893M 605M -34M -41M
Change in payables (cash effect) (USD) -7.64M 29.1M 55.1M 55.5M 27.9M 419M -57M -39M 40M -57M
Dividends paid (cash effect) (USD) -185M -206M -230M -314M -323M -667M -810M -826M -514M -409M
Share buybacks (cash effect) (USD) -127M -58.1M -15.5M 0.00 0.00 — — 0.00 0.00 -38M
Interest paid (cash effect) (USD) -50.6M -55.4M -118M -134M -128M -310M -310M -370M -308M -229M
Income taxes paid (cash effect) (USD) -108M -107M -116M -126M -133M -289M -329M -578M -370M -329M
Share-based compensation (USD) 24.6M 26.6M 29.4M 34.5M 35.8M 54M 49M 65M 77M 88M
Operating cash flow before change in receivables (USD) 557M 460M 488M 639M 775M 1.61B 514M 1.39B 1.29B 918M
Free cash flow (OCF - PPE - intangibles) (USD) 409M 262M 264M 457M 522M 1.04B -109M 936M 602M 254M
Income detail
Research and development expense (USD) 254M 286M 312M 346M 357M 629M 603M 636M 671M 694M
↳ 5y CAGR +3.0% +4.1% +3.7% +6.4% +7.7% +19.9% +16.1% +15.3% +14.2% +14.2%
Total comprehensive income (USD) 338M 338M 273M 441M 383M -455M -2.61B -2.26B -384M 738M
Comprehensive income to owners (USD) 338M 338M 273M 441M 383M -455M -2.62B -2.27B -388M 736M
Provision for credit losses (USD) — — — — 5.92M 6M 19M 9M -4M 6M
Credit cost ratio (credit losses / average receivables) (%) — — — — 1.2% 0.4% 1.0% 0.5% 0.2% 0.4%
Reported Feb 26, 2019 Feb 26, 2019 Mar 3, 2020 Mar 3, 2020 Feb 22, 2021 Feb 28, 2022 Feb 27, 2023 Feb 27, 2026 Feb 27, 2026 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Home Stories Bioscience Por que as biociências estão se tornando fundamentais para a produção moderna de alimentos e bebidas

image 12 (002)

Por que as biociências estão se tornando fundamentais para a produção moderna de alimentos e bebidas

04 November 2026 in: Bioscience Food & Beverage

Bioscience Food & Beverage

Por que as biociências estão se tornando fundamentais para a produção moderna de alimentos e bebidas

Table of Contents

Toggle

De respostas reativas a processos mais resilientes e preparados para o futuro.

A indústria global de alimentos e bebidas vive sob pressão constante. O que antes era um sistema relativamente estável, com fluxos previsíveis de matérias-primas e processos de produção consolidados, tornou-se cada vez mais volátil. Variações climáticas, instabilidade geopolítica e inflação persistente estão redefinindo a forma como os fabricantes operam. Na prática, isso cria um ambiente mais complexo, no qual consistência, eficiência e controle de custos já não são tão fáceis de conciliar.

Simon Bird
Vice-presidente de Food&Beverages – Food Biosciences IFF

Ao mesmo tempo, os órgãos reguladores estão aumentando as exigências relacionadas à nutrição e à sustentabilidade, enquanto os consumidores buscam mais transparência, rótulos mais simples* e práticas de abastecimento mais responsáveis.

Como explica Simon Bird, vice-presidente de Food&Beverages – Food Biosciences da IFF: “os fabricantes estão sendo cada vez mais cobrados por consumidores e órgãos reguladores. As pessoas querem saber como as empresas lidam com a sustentabilidade e esperam mais transparência de quem produz os alimentos” .

Essa combinação de pressões está levando os produtores a repensar não apenas o que fabricam, mas também a forma como produzem. Em setores como panificação e cervejas , marcados por grandes volumes e margens estreitas, o desafio é ainda mais intenso.

Os fabricantes precisam entregar produtos consistentes e de alta qualidade, ao mesmo tempo que administram a variabilidade das matérias-primas, a elevação dos custos e portfólios cada vez mais complexos.

Um sistema sob pressão

A inflação continua impactando nas cadeias globais de suprimentos e elevando os custos de ingredientes , energia e logística. Paralelamente, a variabilidade provocada pelo clima afeta a qualidade e a disponibilidade de matérias-primas essenciais, como trigo e cevada, gerando um grau de imprevisibilidade para o qual os processos tradicionais não foram projetados.

  • Na produção de cervejas , oscilações na qualidade da cevada podem afetar diretamente o desempenho da mosturação e a eficiência da fermentação.
  • Na panificação , variações na funcionalidade da farinha podem comprometer o processamento da massa e a qualidade do produto final. Não são questões secundárias: elas atingem o centro da confiabilidade do processo.

A crescente complexidade dos portfólios amplia ainda mais esse cenário.

As cervejarias agora precisam produzir uma variedade maior de opções de produtos, incluindo cervejas sem álcool ou com baixo teor alcoólico, muitas vezes utilizando a mesma infraestrutura.

Na panificação, as formulações estão sendo ajustadas para aumentar os teores de proteína ou fibras em resposta às tendências de saúde e bem-estar. Cada mudança adiciona complexidade técnica e exige processos mais adaptáveis e resilientes.

Mesmo diante dessas exigências, os fabricantes precisam produzir mais com menos recursos.  Ao mesmo tempo, as metas de sustentabilidade tornaram-se mais ambiciosas, aumentando a pressão para reduzir o uso de água, o consumo de energia e a geração de resíduos.

A ascensão da biociência como ferramenta essencial

Nesse contexto, a inovação em biociências se consolida como uma ferramenta estratégica para aumentar a resiliência. Em vez de funcionar como uma medida corretiva aplicada no fim do processo, soluções de biociências – incluindo tecnologias de enzimas – influenciam a transformação das matérias-primas desde as etapas iniciais do processo.

**Simon descreve essa mudança como algo fundamental: “Ao contrário dos ingredientes tradicionais, a inovação em biociências considera o processo como um todo. O objetivo é criar um processo tolerante e adaptável, sem depender de ações corretivas nas etapas seguintes”, afirma Simon Bird **, vice-presidente de Biociências para Alimentos e Bebidas da IFF.

Essa diferença é importante porque as abordagens tradicionais de formulação costumam corrigir características do produto como textura, estabilidade ou vida útil, depois que a variabilidade já afetou o sistema.

As enzimas atuam em etapas-chave, como mistura, mosturação e fermentação, ajudando a padronizar as matérias-primas e a estabilizar os resultados antes que os problemas ocorram.

  • Na produção de cervejas , isso significa melhorar a quebra de moléculas complexas durante a mosturação, favorecendo uma extração mais eficiente e uma fermentação potencialmente mais previsível, dependendo da matéria-prima e das condições do processo.
  • Na panificação , as enzimas interagem com os componentes da farinha durante o desenvolvimento da massa, fortalecendo sua estrutura e aumentando a tolerância às variações.

O resultado pode ser um processo mais robusto, capaz de contribuir para um desempenho mais consistente quando a qualidade das matérias-primas oscila ou as condições de produção mudam, dependendo da aplicação e dos parâmetros do processo.

Como as enzimas tornam os processos mais resilientes

Um dos benefícios mais imediatos da inovação em biociências é o aumento da confiabilidade dos processos.

Na panificação industrial, linhas de alta velocidade submetem a massa a condições exigentes. Pequenas inconsistências podem causar defeitos, desperdícios e paradas operacionais custosas. Ao reforçar a estrutura da massa , as soluções enzimáticas ajudam a preservar elasticidade, retenção de gases e estabilidade, mantendo o volume e a textura desejados mesmo em condições desafiadoras.

Como observa Simon: “Com uma estrutura de massa mais resiliente, evita-se o colapso e a perda de volume. Isso pode reduzir as rejeições e, consequentemente, o desperdício.”

Essa capacidade de absorver variações é igualmente valiosa quando as características das matérias-primas mudam de forma inesperada. Seja por interrupções na cadeia de suprimentos ou por sazonalidade, os produtores precisam trabalhar com uma variedade maior de insumos. As enzimas funcionam como um amortecedor, favorecendo resultados consistentes sem exigir reformulações constantes.

Na produção de cervejas, o princípio é semelhante. Ao otimizar reações nas etapas iniciais, as enzimas tornam as fases seguintes mais eficientes, reduzem a necessidade de correções e melhoram o rendimento geral. Esse controle antecipado pode contribuir para uma produção mais estável e para a redução do consumo de recursos.

Eficiência, sustentabilidade e custos em sintonia

Um dos aspectos mais relevantes das soluções de biociências é sua capacidade de alinhar eficiência operacional às metas de sustentabilidade. Dependendo do processo e das condições de produção, as enzimas podem contribuir para aumentar o rendimento, reduzir desperdícios e otimizar o uso de recursos, gerando potenciais benefícios econômicos e ambientais. Na prática, isso significa (dependendo do processo:

  • Potencial redução de lotes rejeitados
  • Potencial redução de retrabalho
  • Possibilidade de uso mais eficiente de água e energia
  • Possibilidade de ampliar a vida útil dos produtos, especialmente na panificação, dependendo da formulação, do processo e das condições de armazenamento; o frescor pode contribuir para reduzir perdas ao longo da cadeia de valor

Esses ganhos podem ser alcançados sem aumentar a complexidade da formulação. As enzimas podem permitir a redução de aditivos declarados e listas de ingredientes mais simples, conforme a regulamentação local, sem comprometer o desempenho, dependendo da formulação e do processo – uma vantagem cada vez mais importante diante da demanda por rótulos mais simples*.

A forma de avaliar os custos também muda.

Como explica Simon: “É preciso olhar além do custo de uso e considerar o custo do sistema como um todo. Ao eliminar ineficiências, conseguimos gerar um valor significativo.”

Em vez de considerar apenas o custo dos ingredientes, os fabricantes podem reduzir o custo total de produção ao melhorar a eficiência do processo.

Apoiando o futuro da produção de alimentos

Glass filled with barley grains placed on a large pile of barley

Olhando para o futuro, as biociências terão um papel ainda mais relevante na produção de alimentos. À medida que a variabilidade climática se intensifica e as expectativas dos consumidores evoluem, cresce também a necessidade de sistemas produtivos mais flexíveis e resilientes.

A inovação em biociências oferece um caminho para enfrentar esses desafios, permitindo extrair mais valor dos recursos disponíveis sem abrir mão de qualidade e acessibilidade.

Isso também abre espaço para novos formatos de produtos, de itens de panificação com melhor perfil nutricional a categorias inovadoras de bebidas, sem exigir mudanças profundas na infraestrutura existente.

Para Simon, é isso que torna essa área tão relevante. “Não se trata apenas de resolver os problemas de hoje, mas de pensar em como alimentaremos o mundo no futuro”, afirma.

Com atuação em inovação no setor de alimentos e biociências, a IFF ajuda fabricantes a transformar ambição em resultados concretos. Do desenvolvimento de moléculas e enzimas à produção em escala industrial, nossa combinação de tecnologias, presença global, expertise técnica e suporte local contribui para transformar conceitos em soluções aplicáveis e resultados reais para a indústria.

Em uma indústria marcada por mudanças constantes, as biociências deixaram de ser uma ferramenta complementar. Elas se tornaram uma capacidade essencial, que ajuda fabricantes de todo o mundo a substituir a solução reativa de problemas pelo desenvolvimento proativo de sistemas produtivos mais resilientes e eficientes, que podem contribuir para resultados de sustentabilidade, dependendo do processo e das condições de produção.

* “Rótulos mais simples” refere-se à possibilidade de reduzir aditivos declarados ou simplificar a lista de ingredientes, conforme a regulamentação local e dependendo da formulação, do processo e do produto.

Get to know more from our experts

Partner with us

Topics: Baking Enzymes brewing enzymes Enzymes Food Biosciences

Share IFF News & Innovation

Related Stories

View All

Por qué las biociencias se están volviendo fundamentales para la producción moderna de alimentos y bebidas

Por qué las biociencias se están volviendo fundamentales para la producción moderna de alimentos y bebidas

04 November 2026

Turning up the heat: evaluating thermal treatments for phage management in dairy plants

Turning up the heat: evaluating thermal treatments for phage management in dairy plants

01 October 2026

An updated evolutionary classification of CRISPR–Cas systems including rare variants

An updated evolutionary classification of CRISPR–Cas systems including rare variants

01 October 2026

logo

Copyright 2026 © by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

Home Stories Bioscience Por qué las biociencias se están volviendo fundamentales para la producción moderna de alimentos y bebidas

image 12 (002)

Por qué las biociencias se están volviendo fundamentales para la producción moderna de alimentos y bebidas

04 November 2026 in: Bioscience Food & Beverage

Bioscience Food & Beverage

Por qué las biociencias se están volviendo fundamentales para la producción moderna de alimentos y bebidas

Table of Contents

Toggle

De respuestas reactivas a procesos más resilientes y preparados para el futuro.

La industria global de alimentos y bebidas está sometida a una presión constante. Lo que antes era un sistema relativamente estable, con flujos previsibles de materias primas y procesos de producción consolidados, se ha vuelto cada vez más volátil. Las variaciones climáticas, la inestabilidad geopolítica y la inflación persistente están redefiniendo la forma en que operan los fabricantes. En la práctica, esto crea un entorno más complejo, en el que ya no resulta tan fácil conciliar la consistencia, la eficiencia y el control de costos.

Simon Bird
Vicepresidente Food & Beverages Biosciences IFF

Al mismo tiempo, los organismos reguladores están elevando las exigencias relacionadas con la nutrición y la sostenibilidad, mientras que los consumidores buscan mayor transparencia, etiquetas más simples* y prácticas de abastecimiento más responsables.

Como explica Simon Bird, VP de Food & Beverage Biosciences en IFF , “Los fabricantes están cada vez más sometidos al escrutinio de consumidores y organismos reguladores. Las personas quieren saber cómo gestionan las empresas la sostenibilidad y esperan mayor transparencia de quienes producen los alimentos”.

Esta combinación de presiones está llevando a los productores a replantearse no solo qué fabrican, sino también cómo lo producen. En sectores como la panificación y la elaboración de cerveza , caracterizados por grandes volúmenes y márgenes estrechos, el desafío es aún más intenso.

Los fabricantes deben ofrecer productos consistentes y de alta calidad, al mismo tiempo que gestionan la variabilidad de las materias primas, el aumento de los costos y portafolios cada vez más complejos.

Un sistema bajo presión

La inflación continúa repercutiendo en las cadenas globales de suministro y elevando el costo de los ingredientes , la energía y la logística. Al mismo tiempo, la variabilidad provocada por el clima afecta la calidad y la disponibilidad de materias primas esenciales, como el trigo y la cebada, generando un grado de imprevisibilidad para el que los procesos tradicionales no fueron diseñados.

  • En la elaboración de cerveza , las fluctuaciones en la calidad de la cebada pueden afectar directamente el desempeño de la maceración y la eficiencia de la fermentación.
  • En la panificación , las variaciones en la funcionalidad de la harina pueden comprometer el procesamiento de la masa y la calidad del producto final. No son cuestiones secundarias: afectan el núcleo mismo de la confiabilidad del proceso.

La creciente complejidad de los portafolios amplifica aún más este escenario.

Las cervecerías ahora deben producir una variedad más amplia de opciones, incluidas cervezas sin alcohol o con bajo contenido alcohólico, a menudo utilizando la misma infraestructura.

En panificación, las formulaciones se están ajustando para aumentar el contenido de proteína o fibra en respuesta a las tendencias de salud y bienestar. Cada cambio añade complejidad técnica y exige procesos más adaptables y resilientes.

Incluso ante estas exigencias, los fabricantes deben producir más con menos recursos. Al mismo tiempo, las metas de sostenibilidad se han vuelto más ambiciosas, aumentando la presión para reducir el uso de agua, el consumo de energía y la generación de residuos.

El auge de las biociencias como herramienta esencial

En este contexto, la innovación en biociencias se consolida como una herramienta estratégica para aumentar la resiliencia. En lugar de funcionar como una medida correctiva aplicada al final del proceso, las soluciones de biociencias – incluidas las tecnologías de enzimas – influyen en la transformación de las materias primas desde las etapas iniciales del proceso.

Simon Bird, vicepresidente de Biociencias para Food & Beverages Biosciences IFF, describe este cambio como algo fundamental: “A diferencia de los ingredientes tradicionales, la innovación en biociencias considera el proceso en su conjunto. El objetivo es crear un proceso tolerante y adaptable, sin depender de acciones correctivas en las etapas posteriores”.

Esta diferencia es importante porque los enfoques tradicionales de formulación suelen corregir características del producto, como la textura, la estabilidad o la vida útil, después de que la variabilidad ya ha afectado el sistema.

Las enzimas actúan en etapas clave, como la mezcla, la maceración y la fermentación, ayudando a estandarizar las materias primas y a estabilizar los resultados antes de que surjan los problemas.

  • En la elaboración de cerveza , esto significa mejorar la descomposición de moléculas complejas durante la maceración, favoreciendo una extracción más eficiente y una fermentación potencialmente más predecible, dependiendo de la materia prima y de las condiciones del proceso.
  • En la panificación , las enzimas interactúan con los componentes de la harina durante el desarrollo de la masa, fortaleciendo su estructura y aumentando su tolerancia a las variaciones.

El resultado puede ser un proceso más robusto, capaz de contribuir a un desempeño más consistente cuando fluctúa la calidad de las materias primas o cambian las condiciones de producción, dependiendo de la aplicación y de los parámetros del proceso.

Cómo las enzimas hacen que los procesos sean más resilientes

Uno de los beneficios más inmediatos de la innovación en biociencias es el aumento de la confiabilidad de los procesos.

En la panificación industrial, las líneas de alta velocidad someten la masa a condiciones exigentes. Pequeñas inconsistencias pueden causar defectos, desperdicios y paradas costosas. Al reforzar la estructura de la masa , las soluciones enzimáticas ayudan a preservar la elasticidad, la retención de gases y la estabilidad, manteniendo el volumen y la textura deseados incluso en condiciones desafiantes.

Como señala Simon: “Con una estructura de masa más resiliente, se evita el colapso y la pérdida de volumen. Esto puede reducir los rechazos y, en consecuencia, el desperdicio”.

Esta capacidad de absorber variaciones es igualmente valiosa cuando las materias primas cambian de forma inesperada. Ya sea por interrupciones en la cadena de suministro o por factores estacionales, los productores deben trabajar con una mayor variedad de insumos. Las enzimas actúan como un amortiguador, favoreciendo resultados consistentes sin exigir reformulaciones constantes.

En la elaboración de cerveza, el principio es similar. Al optimizar las reacciones en las primeras etapas, las enzimas hacen que las fases posteriores sean más eficientes, reducen la necesidad de correcciones y mejoran el rendimiento general. Este control anticipado puede contribuir a una producción más estable y a reducir el consumo de recursos, dependiendo del proceso y de las condiciones de producción.

Eficiencia, sostenibilidad y costos en sintonía

Uno de los aspectos más relevantes de las soluciones de biociencias es su capacidad para alinear la eficiencia operativa con las metas de sostenibilidad. Dependiendo del proceso y de las condiciones de producción, las enzimas pueden contribuir a aumentar el rendimiento, reducir los desperdicios y optimizar el uso de recursos, generando posibles beneficios económicos y ambientales. En la práctica, esto significa, dependiendo del proceso:

  • Posible reducción de lotes rechazados
  • Posible reducción de reprocesos
  • Posibilidad de un uso más eficiente del agua y la energía,
  • Posibilidad de ampliar la vida útil de los productos, especialmente en panificación, dependiendo de la formulación, el proceso y las condiciones de almacenamiento; la frescura puede contribuir a reducir las pérdidas a lo largo de la cadena de valor

Estos beneficios pueden lograrse sin aumentar la complejidad de la formulación. Las enzimas pueden permitir reducir los aditivos declarados y simplificar las listas de ingredientes, de acuerdo con la normativa local, sin comprometer el desempeño, dependiendo de la formulación y del proceso; una ventaja cada vez más importante ante la demanda de etiquetas más simples*. La forma de evaluar los costos también está cambiando.

Como explica Simon: “Es necesario mirar más allá del costo de uso y considerar el costo del sistema en su conjunto. Al eliminar ineficiencias, podemos generar un valor significativo”.

En lugar de considerar únicamente el precio de los ingredientes, los fabricantes pueden reducir el costo total de producción al mejorar la eficiencia del proceso.

Apoyando el futuro de la producción de alimentos

Glass filled with barley grains placed on a large pile of barley

De cara al futuro, las biociencias desempeñarán un papel aún más relevante en la producción de alimentos. A medida que se intensifica la variabilidad climática y evolucionan las expectativas de los consumidores, también crece la necesidad de contar con sistemas productivos flexibles y resilientes.

La innovación en biociencias ofrece un camino para afrontar estos desafíos, permitiendo obtener mayor valor de los recursos disponibles sin renunciar a la calidad ni a la accesibilidad.

También abre espacio para nuevos formatos de productos, desde productos de panificación con un mejor perfil nutricional hasta categorías innovadoras de bebidas, sin exigir cambios profundos en la infraestructura existente.

Para Simon, eso es lo que hace que esta área sea tan relevante. “No se trata solo de resolver los problemas de hoy, sino de pensar en cómo alimentaremos al mundo en el futuro”, afirma.

Con actuación en innovación en el sector de alimentos y biociencias, IFF ayuda a los fabricantes a transformar sus ambiciones en resultados concretos. Desde el desarrollo de moléculas y enzimas hasta la producción a escala industrial, nuestra combinación de tecnologías, presencia global, experiencia técnica y soporte local contribuye a transformar conceptos en soluciones aplicables y resultados reales para la industria.

En una industria marcada por cambios constantes, las biociencias han dejado de ser una herramienta complementaria. Se han convertido en una capacidad esencial que ayuda a los fabricantes de todo el mundo a sustituir la resolución reactiva de problemas por el desarrollo proactivo de sistemas productivos más resilientes y eficientes, que pueden contribuir a resultados de sostenibilidad, dependiendo del proceso y de las condiciones de producción.

* “Etiquetas más simples” se refiere a la posibilidad de reducir los aditivos declarados o simplificar la lista de ingredientes, de acuerdo con la normativa local y dependiendo de la formulación, el proceso y el producto.

Get to know more from our experts

Partner with us

Topics: Baking Enzymes brewing enzymes Enzymes

Share IFF News & Innovation

Related Stories

View All

Por que as biociências estão se tornando fundamentais para a produção moderna de alimentos e bebidas

Por que as biociências estão se tornando fundamentais para a produção moderna de alimentos e bebidas

04 November 2026

Turning up the heat: evaluating thermal treatments for phage management in dairy plants

Turning up the heat: evaluating thermal treatments for phage management in dairy plants

01 October 2026

An updated evolutionary classification of CRISPR–Cas systems including rare variants

An updated evolutionary classification of CRISPR–Cas systems including rare variants

01 October 2026

logo

Copyright 2026 © by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

IFF Reports Third Quarter 2026 Results Bull 4 Bear 0 Results

Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026

Raising Low-End of Full Year 2026 Financial Guidance Ranges

Recently Completed $500M Share Repurchase Authorization

Food Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027

NEW YORK--(BUSINESS WIRE)--Nov. 3, 2026-- IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2026. Results are presented on a continuing operations basis, excluding the Food Ingredients business and other minor perimeter adjustments (the “Food Ingredients disposal group”), and the Soy Crush, Concentrates, and Lecithin businesses (the “SCL disposal group”). The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations.

Third Quarter 2026 Consolidated Summary of Results, on a continuing operations basis1:

| Reported**(GAAP)** | | Adjusted**(Non-GAAP)2** |

| Sales | | Loss Before Taxes | | EPS | | Operating EBITDA | | Operating EBITDA Margin | | EPS ex Amortization |

| $1.9 B | | $(134) M | | $(0.50) | | $403 M | | 20.8% | | $0.83 |

First Nine Months 2026 Consolidated Summary of Results, on a continuing operations basis1:

| Reported**(GAAP)** | | Adjusted**(Non-GAAP)2** |

| Sales | | Income Before Taxes | | EPS | | Operating EBITDA | | Operating EBITDA Margin | | EPS ex Amortization |

| $5.8 B | | $126 M | | $0.23 | | $1.2 B | | 21.4% | | $2.58 |

Management Commentary

“IFF delivered a solid third quarter, with improved sales and profitability across all divisions,” said Erik Fyrwald, CEO of IFF. “Taste and Scent delivered strong top- and bottom-line results, and Health & Biosciences improved modestly as we continue to strengthen the business. We also generated strong cash flow through the first nine months of 2026 and recently completed our $500 million accelerated share repurchase program. The separation of Food Ingredients is progressing well, and we are on track with our timeline to close.”

“Heading into year-end, we are raising the low end of our full-year financial guidance ranges, supported by our year-to-date performance. Volumes remain solid as customers continue to value our strong R&D and innovation. At the same time, we expect fourth-quarter profitability to be softer, particularly in Health & Biosciences, reflecting higher costs as well as reinvestments to strengthen the business. Amid changing macroeconomic conditions, we remain focused on what we can control and are delivering on the financial commitments we set out earlier this year. Our continued execution and these actions give us confidence to deliver results within our full-year financial outlook and our ability to create long-term value for shareholders.”

Third Quarter 2026 Consolidated Financial Results1

  • Reported net sales for the third quarter were $1.94 billion, an increase of 4% versus the prior-year period. On a comparable basis3, currency neutral sales2 increased 5% versus the prior-year period led by broad-based growth including mid-single digit performances in Scent and Taste and low-single digit growth in Health & Biosciences.

  • Loss from continuing operations before taxes on a reported basis for the third quarter was $(134) million. Adjusted operating EBITDA2 for the third quarter was $403 million. On a comparable basis3, currency neutral adjusted operating EBITDA2 improved 6% versus the prior-year period, driven by volume growth.

  • Reported earnings per share (EPS) for the third quarter was $(0.50) per diluted share. Adjusted EPS excluding amortization2 was $0.83 per diluted share.

  • Cash flows from operations for the first nine months of the year for continuing and discontinued operations were $820 million, increasing $288 million year-over-year, and free cash flow2, defined as cash flows from operations less capital expenditures, totaled $371 million, increasing $245 million year-over-year. Total debt to trailing twelve months net income at the end of the third quarter was 34.5x. Net debt to credit adjusted EBITDA2 at the end of the third quarter was 2.75x, and includes the effects of both continuing and discontinued operations.

Third Quarter 2026 Segment Summary1: Growth vs. Prior Year

| | Reported**(GAAP)** | | Comparable Currency Neutral**(Non-GAAP)2 3** | | Adjusted**(Non-GAAP)2** | | Comparable Currency NeutralAdjusted(Non-GAAP)2 3 |

| | Sales | | Sales | | Operating EBITDA | | Operating EBITDA |

| Taste | 4% | | 6% | | 4% | | 7% |

| Health & Biosciences | 1% | | 1% | | 1% | | 2% |

| Scent | 6% | | 6% | | 9% | | 10% |

| Consolidated | 4% | | 5% | | 5% | | 6% |

Taste Segment

  • On a reported basis, third quarter sales were $687 million. On a comparable basis3, currency neutral sales2 increased 6% with broad-based growth in all regions led by a double-digit increase in Greater Asia.

  • Taste adjusted operating EBITDA2 was $128 million and adjusted operating EBITDA margin2 was 18.6% in the third quarter. On a comparable basis3, currency neutral adjusted operating EBITDA2 increased 7% driven by volume growth.

Health & Biosciences Segment

  • On a reported basis, third quarter sales were $566 million. On a comparable basis3, currency neutral sales2 increased 1% with growth in nearly all businesses. Mid-single digit growth in Food Biosciences and Grain Processing more than offset a decline in Health.

  • Health & Biosciences adjusted operating EBITDA2 was $136 million and adjusted operating EBITDA margin2 was 24.0% in the third quarter. On a comparable basis3, currency neutral adjusted operating EBITDA2 increased 2% with the contribution split evenly between volume growth and favorable net price to input costs.

Scent Segment

  • On a reported basis, third quarter sales were $689 million. On a comparable basis3, currency neutral sales2 increased 6% led by high-single digit growth in Consumer Fragrances. Fine Fragrance, against a strong double digit year ago comparable, and Fragrance Ingredients both grew mid-single digits.

  • Scent adjusted operating EBITDA2 was $139 million and adjusted operating EBITDA margin2 was 20.2% in the third quarter. On a comparable basis3, currency neutral adjusted operating EBITDA2 increased 10% driven by volume growth.

Financial Guidance1

The Company provides financial guidance for continuing operations to reflect the separation of the Food Ingredients disposal group and SCL disposal group as discontinued operations. The Company now expects full year 2026 sales to be in the range of $7.5 billion to $7.6 billion (versus $7.4 billion to $7.6 billion previously). For the full year 2026 adjusted operating EBITDA is now expected to be in the range of $1.55 billion to $1.60 billion (versus $1.53 billion to $1.60 billion previously).

On a continuing operations basis, the Company now expects comparable currency neutral sales growth to be between 3% to 4% (versus 2% to 4% previously), and comparable currency neutral adjusted operating EBITDA growth to be 5% to 8% (versus 4% to 8% previously).

Based on recent market foreign exchange rates, the Company continues to expect that foreign exchange will have an approximately 1% positive impact on sales growth and have an approximately 2% positive impact on adjusted operating EBITDA growth in 2026.

Audio Webcast

A live webcast to discuss the Company’s third quarter 2026 financial results will be held on November 4, 2026, at 9:00 a.m. ET. The webcast and accompanying slide presentation may be accessed on the Company’s IR website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event and will remain available on IFF’s website for one year.

Cautionary Statement Under The Private Securities Litigation Reform Act of 1995

This press release includes statements that are not historical facts and are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on management’s current assumptions, estimates and expectations, including with respect to our financial and operational outlook (sales, adjusted operating EBITDA and cash flow), portfolio optimization initiatives (including the pending divestiture of our Food Ingredients disposal group and the expected timing and benefits thereof), pricing, productivity and cost-discipline actions, capital allocation, future operations, growth potential, strategic investments and the expected effects of foreign exchange. These statements reflect management’s present views, are based on a series of expectations, assumptions, estimates and projections about the Company, are subject to change, and involve uncertainties that could cause actual results to differ materially.

Certain of such forward-looking information may be identified by such terms as “expect”, “anticipate”, “believe”, “intend”, “outlook”, “may”, “will”, “would”, “estimate”, “should”, “predict”, “plan”, “project”, “could”, “potential”, “seek”, “target”, “continue”, “future”, and similar terms or variations thereof. These statements are not guarantees of future performance and are subject to risks and uncertainties that could lead to materially different outcomes.

Such risks, uncertainties and other factors include, among others, the following: (1) demand trends, competitive dynamics and customer concentration in our end markets; (2) execution of our strategic transformation and other strategic transactions, divestitures, acquisitions, collaborations and joint ventures; (3) working capital and inventory management; (4) outcomes of legal claims, disputes, regulatory investigations and litigation; (5) tariffs and trade actions, supply chain disruptions and macro events, including geopolitical developments, climate events, natural disasters, public health crises; (6) volatility in input costs (such as raw materials, transportation and energy); (7) attraction, retention and turnover of key employees and executives; (8) product innovation, time-to-market, product safety and quality; (9) cybersecurity incidents, artificial intelligence related risks, data privacy and compliance with data protection laws; (10) exposure to emerging markets, foreign currency fluctuations and international regulatory and political risks; (11) capital allocation, dividend policy and potential impairments of tangible or intangible assets; (12) our indebtedness, credit rating, liquidity, and access to capital; (13) pension and postretirement obligations; (14) compliance with federal, state, local and international rules and regulations, and regulatory, environmental, anti-corruption and sanctions laws and related ethical business practices; (15) protection and enforcement of intellectual property; (16) changes in tax laws and policies, tax audits and outcomes, including potential tax liabilities related to prior transactions; and (17) changes in federal, state, local and international rules and regulations.

The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. Important factors are described under “Risk Factors” in our most recent Annual Report on Form 10-K and in our subsequent filings with the SEC, and those disclosures are incorporated herein by reference.

We intend our forward-looking statements to speak only as of the time of such statements and do not undertake or plan to update or revise them as more information becomes available or to reflect changes in expectations, assumptions or results, whether as a result of new information, future events or otherwise. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this press release or included in our other periodic reports filed with the SEC could materially and adversely impact our operations and our future financial results.

Any public statements or disclosures made by us following this press release that modify or impact any of the forward-looking statements contained in or accompanying this press release will be deemed to modify or supersede such outlook or other forward-looking statements in or accompanying this press release.

Use of Non-GAAP Financial Measures

We provide in this press release non-GAAP financial measures, including: (i) comparable currency neutral sales; (ii) adjusted operating EBITDA and comparable currency neutral adjusted operating EBITDA; (iii) adjusted operating EBITDA margin; (iv) adjusted EPS ex amortization; (v) free cash flow; and (vi) net debt to credit adjusted EBITDA. Unless otherwise noted, all amounts and percentages in this press release reflect the results from continuing operations, with the exception of the Statements of Cash Flows and net debt to credit adjusted EBITDA which are presented on a combined continuing and discontinued basis.

Our non-GAAP financial measures are defined below.

Currency Neutral metrics eliminate the effects that result from translating non-U.S. currencies to U.S. dollars. We calculate currency neutral numbers by translating current year invoiced sale amounts at the exchange rates used for the corresponding prior year period. We use currency neutral results in our analysis of segment performance. We also use currency neutral numbers when analyzing our performance against that of our competitors.

Comparable results for the third quarter exclude the impact of divestitures.

Adjusted operating EBITDA and adjusted operating EBITDA margin exclude depreciation and amortization, interest expense, other expense, net, and certain non-recurring or unusual items that are not part of recurring operations such as impairment of goodwill, restructuring and other charges, losses (gains) on business disposals, loss on assets classified as held for sale, divestiture costs, strategic initiatives costs, regulatory costs, gain on debt extinguishment, entity realignment and other items.

Adjusted EPS ex Amortization excludes the impact of non-operational items including restructuring and other charges, divestiture costs, losses (gains) on business disposals, strategic initiatives costs, regulatory costs and other items that are not a part of recurring operations.

Free Cash Flow is operating cash flow (i.e., cash flow from operations) less capital expenditures.

Net debt to credit adjusted EBITDA is the leverage ratio used in our credit agreements and defined as net debt (which is debt for borrowed money less cash and cash equivalents) divided by the trailing 12-month credit adjusted EBITDA. Credit adjusted EBITDA is defined as income (loss) before interest expense, income taxes, depreciation and amortization, specified items and non-cash items.

These non-GAAP measures are intended to provide additional information regarding our underlying operating results and comparable year-over-year performance. Such information is supplemental to information presented in accordance with GAAP and is not intended to represent a presentation in accordance with GAAP. In discussing our historical and expected future results and financial condition, we believe it is meaningful for investors to be made aware of and to be assisted in a better understanding of, on a period-to-period comparable basis, financial amounts both including and excluding these identified items, as well as the impact of exchange rate fluctuations. These non-GAAP measures should not be considered in isolation or as substitutes for analysis of the Company’s results under GAAP and may not be comparable to other companies’ calculations of such metrics.

The Company cannot reconcile its expected adjusted operating EBITDA or comparable currency neutral growth rates under "Financial Guidance" to the most directly comparable GAAP measures without unreasonable effort because certain items that impact net income and other reconciling metrics are out of the Company's control and/or cannot be reasonably predicted at this time. These items include but are not limited to divestiture costs, gains (losses) on business disposals, and regulatory costs, and their probable significance cannot be determined at this time but could be material to the Company’s GAAP results.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

| _______________________ |

| 1 Unless otherwise noted, results are presented on a continuing operations basis, reflecting the Food Ingredients disposal group and the SCL disposal group as discontinued operations. See pages 5-6 for further information, including the basis of presentation included in this release. |

| 2 Schedules at the end of this release contain reconciliations of reported GAAP to Non-GAAP metrics. See Use of Non-GAAP Financial Measures for explanations of our Non-GAAP metrics. |

| 3 Comparable results for the third quarter exclude the impact of divestitures. |

| International Flavors & Fragrances Inc. |

| Consolidated Statements of Income (Loss) |

| (Amounts in millions except per share data) |

| (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | % Change | | | 2026 | | | | 2025 | | | % Change |

| Net sales | $ | 1,942 | | | $ | 1,869 | | | 4 | % | | $ | 5,802 | | | $ | 5,838 | | | (1 | )% |

| Cost of sales | | 1,117 | | | | 1,070 | | | 4 | % | | | 3,295 | | | | 3,363 | | | (2 | )% |

| Gross profit | | 825 | | | | 799 | | | 3 | % | | | 2,507 | | | | 2,475 | | | 1 | % |

| Research and development expenses | | 170 | | | | 162 | | | 5 | % | | | 494 | | | | 487 | | | 1 | % |

| Selling and administrative expenses | | 387 | | | | 348 | | | 11 | % | | | 1,158 | | | | 1,147 | | | 1 | % |

| Amortization of acquisition-related intangibles | | 78 | | | | 84 | | | (7 | )% | | | 244 | | | | 246 | | | (1 | )% |

| Impairment of goodwill | | 23 | | | | — | | | NMF | | | 23 | | | | 34 | | | NMF |

| Restructuring and other charges | | 5 | | | | 14 | | | (64 | )% | | | 15 | | | | 49 | | | (69 | )% |

| Losses on sale of assets | | 2 | | | | — | | | NMF | | | 2 | | | | 1 | | | 100 | % |

| Operating profit | | 160 | | | | 191 | | | (16 | )% | | | 571 | | | | 511 | | | 12 | % |

| Interest expense | | 46 | | | | 48 | | | (4 | )% | | | 136 | | | | 180 | | | (24 | )% |

| Gain on extinguishment of debt | | — | | | | — | | | NMF | | | — | | | | (488 | ) | | NMF |

| (Gains) losses on business disposals | | (2 | ) | | | — | | | NMF | | | (1 | ) | | | 111 | | | (101 | )% |

| Loss on assets classified as held for sale | | 236 | | | | — | | | NMF | | | 263 | | | | — | | | NMF |

| Other expense, net | | 14 | | | | 13 | | | 8 | % | | | 47 | | | | 52 | | | (10 | )% |

| (Loss) Income from continuing operations before taxes | | (134 | ) | | | 130 | | | (203 | )% | | | 126 | | | | 656 | | | (81 | )% |

| (Benefit) Provision for income taxes | | (7 | ) | | | 31 | | | (123 | )% | | | 65 | | | | (61 | ) | | (207 | )% |

| Net (loss) income from continuing operations | | (127 | ) | | | 99 | | | (228 | )% | | | 61 | | | | 717 | | | (91 | )% |

| Income (loss) from discontinued operations before tax | | 99 | | | | (74 | ) | | (234 | )% | | | 143 | | | | (1,090 | ) | | (113 | )% |

| Provision (benefit) for income taxes from discontinued operations | | 27 | | | | (16 | ) | | (269 | )% | | | 38 | | | | 4 | | | NMF |

| Net income (loss) from discontinued operations | | 72 | | | | (58 | ) | | (224 | )% | | | 105 | | | | (1,094 | ) | | (110 | )% |

| Net (loss) income | | (55 | ) | | | 41 | | | (234 | )% | | | 166 | | | | (377 | ) | | (144 | )% |

| Net income attributable to non-controlling interests from continuing operations | | — | | | | — | | | NMF | | | 1 | | | | 1 | | | — | % |

| Net income attributable to non-controlling interests from discontinued operations | | — | | | | 1 | | | (100 | )% | | | 1 | | | | 1 | | | — | % |

| Net (loss) income attributable to IFF shareholders | $ | (55 | ) | | $ | 40 | | | (238 | )% | | $ | 164 | | | $ | (379 | ) | | (143 | )% |

| | | | | | | | | | | | |

| Net (loss) income per share - basic | | | | | | | | | | | |

| Continuing operations | $ | (0.50 | ) | | $ | 0.39 | | | | | $ | 0.24 | | | $ | 2.81 | | | |

| Discontinued operations | | 0.28 | | | | (0.23 | ) | | | | | 0.41 | | | | (4.29 | ) | | |

| Net (loss) income per share - basic | $ | (0.22 | ) | | $ | 0.16 | | | | | $ | 0.65 | | | $ | (1.48 | ) | | |

| Net (loss) income per share - diluted | | | | | | | | | | | |

| Continuing operations | $ | (0.50 | ) | | $ | 0.39 | | | | | $ | 0.23 | | | $ | 2.80 | | | |

| Discontinued operations | | 0.28 | | | | (0.23 | ) | | | | | 0.41 | | | | (4.28 | ) | | |

| Net (loss) income per share - diluted | $ | (0.22 | ) | | $ | 0.16 | | | | | $ | 0.64 | | | $ | (1.48 | ) | | |

| | | | | | | | | | | | |

| Average number of shares outstanding | | | | | | | | | | | |

| Average number of shares outstanding - basic | | 253 | | | | 256 | | | | | | 254 | | | | 255 | | | |

| Average number of shares outstanding - diluted | | 253 | | | | 257 | | | | | | 255 | | | | 256 | | | |

| NMF Not meaningful |

| International Flavors & Fragrances Inc. |

| Condensed Consolidated Balance Sheets |

| (Amounts in millions) |

| (Unaudited) |

| |

| | September 30, | | December 31, |

| | 2026 | | 2025 |

| Cash and cash equivalents | $ | 272 | | $ | 347 |

| Receivables, net | | 1,416 | | | 1,294 |

| Inventories | | 1,452 | | | 1,507 |

| Prepaid expenses and other current assets | | 954 | | | 742 |

| Current assets of discontinued operations | | 5,181 | | | 1,704 |

| Total current assets | | 9,275 | | | 5,594 |

| | | | |

| Property, plant and equipment, net | | 2,648 | | | 2,685 |

| Goodwill and other intangibles, net | | 11,553 | | | 12,190 |

| Other assets | | 1,349 | | | 1,469 |

| Non-current assets of discontinued operations | | — | | | 3,601 |

| Total assets | $ | 24,825 | | $ | 25,539 |

| | | | |

| Short-term borrowings | $ | 1,538 | | $ | 1,254 |

| Other current liabilities | | 2,280 | | | 2,129 |

| Current liabilities of discontinued operations | | 1,140 | | | 550 |

| Total current liabilities | | 4,958 | | | 3,933 |

| | | | |

| Long-term debt | | 4,735 | | | 4,738 |

| Non-current liabilities | | 1,842 | | | 2,065 |

| Non-current liabilities of discontinued operations | | — | | | 617 |

| | | | |

| Total Shareholders' equity including Non-controlling interests | | 13,290 | | | 14,186 |

| Total liabilities and shareholders' equity | $ | 24,825 | | $ | 25,539 |

| International Flavors & Fragrances Inc. |

| Consolidated Statements of Cash Flows(1) |

| (Amounts in millions) |

| (Unaudited) |

| |

| | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | |

| Cash flows from operating activities: | | | |

| Net income (loss) | $ | 166 | | | $ | (377 | ) |

| Adjustments to reconcile to net cash provided by operating activities | | | |

| Depreciation and amortization | | 614 | | | | 725 | |

| Deferred income taxes | | (99 | ) | | | (226 | ) |

| Loss on assets classified as held for sale | | 263 | | | | 108 | |

| Losses on sale of assets | | 2 | | | | 1 | |

| Losses on business disposals | | 6 | | | | 111 | |

| Stock-based compensation | | 71 | | | | 72 | |

| Pension contributions | | (14 | ) | | | (20 | ) |

| Gain on extinguishment of debt | | — | | | | (488 | ) |

| Impairment of goodwill | | 23 | | | | 1,153 | |

| Changes in assets and liabilities, net of acquisitions: | | | |

| Trade receivables | | (291 | ) | | | (195 | ) |

| Inventories | | (54 | ) | | | (129 | ) |

| Accounts payable | | 204 | | | | 28 | |

| Accruals for incentive compensation | | 24 | | | | (154 | ) |

| Other assets/liabilities, net | | (95 | ) | | | (77 | ) |

| Net cash provided by operating activities | | 820 | | | | 532 | |

| Cash flows from investing activities: | | | |

| Additions to property, plant and equipment | | (449 | ) | | | (406 | ) |

| Additions to intangible assets | | (2 | ) | | | (2 | ) |

| Joint venture capital contributions | | — | | | | (4 | ) |

| Net proceeds received from business disposals | | 247 | | | | 2,707 | |

| Payments to buyer for business disposals | | (12 | ) | | | — | |

| Cash (paid) received on foreign currency forward contracts | | (58 | ) | | | 131 | |

| Net cash (used in) provided by investing activities | | (274 | ) | | | 2,426 | |

| Cash flows from financing activities: | | | |

| Cash dividends paid to shareholders | | (306 | ) | | | (306 | ) |

| Net borrowings of commercial paper (maturities less than three months) | | 224 | | | | 370 | |

| Principal payments of debt | | (912 | ) | | | (2,913 | ) |

| Proceeds from Delayed Draw Term Loan Facility | | 1,000 | | | | — | |

| Withholding tax paid on stock-based compensation | | (19 | ) | | | (23 | ) |

| Purchases of treasury stock | | (584 | ) | | | — | |

| Other, net | | (12 | ) | | | (19 | ) |

| Net cash used in financing activities | | (609 | ) | | | (2,891 | ) |

| Effect of exchange rate changes on cash and cash equivalents | | (8 | ) | | | 83 | |

| Net change in cash and cash equivalents | | (71 | ) | | | 150 | |

| Cash and cash equivalents at beginning of year | | 590 | | | | 471 | |

| Cash and cash equivalents at end of period | $ | 519 | | | $ | 621 | |

| (1) The cash flows from discontinued operations are included in the Consolidated Statements of Cash Flows. |

The following table reconciles cash and cash equivalents between the Company's statement of cash flows for the periods ended September 30, 2026 and September 30, 2025 to the amounts reported on the Company's balance sheet:

| AMOUNTS IN MILLIONS | September 30, 2026 | | December 31, 2025 | | September 30, 2025 | | December 31, 2024 |

| Current assets | | | | | | | |

| Cash and cash equivalents | $ | 272 | | $ | 347 | | $ | 399 | | $ | 312 |

| Cash and cash equivalents included in Assets held for sale | | 5 | | | — | | | — | | | 2 |

| Cash and cash equivalents included in Current assets of discontinued operations | | 242 | | | 243 | | | 222 | | | 157 |

| Cash and cash equivalents | $ | 519 | | $ | 590 | | $ | 621 | | $ | 471 |

| International Flavors & Fragrances Inc. |

| Reportable Segment Performance |

| (Amounts in millions) |

| (Unaudited) |

| |

| | Three Months Ended September 30, 2026 |

| | Taste | | Health & Biosciences | | Scent | | Total |

| Net Sales | $ | 687 | | | $ | 566 | | | $ | 689 | | | $ | 1,942 |

| Cost of Sales | | (419 | ) | | | (305 | ) | | | (392 | ) | | |

| Research & Development Expenses | | (46 | ) | | | (56 | ) | | | (67 | ) | | |

| Selling & Administrative Expenses | | (116 | ) | | | (105 | ) | | | (112 | ) | | |

| Depreciation Expense Add-back (a) | | 22 | | | | 36 | | | | 21 | | | |

| Adjusted Operating EBITDA | $ | 128 | | | $ | 136 | | | $ | 139 | | | $ | 403 |

| Reconciliation of Adjusted Operating EBITDA: | |

| Total Adjusted Operating EBITDA | $ | 403 | |

| Depreciation & Amortization | | (156 | ) |

| Interest Expense | | (46 | ) |

| Other Expense, net | | (14 | ) |

| Restructuring and Other Charges (b) | | (5 | ) |

| Impairment of Goodwill (c) | | (23 | ) |

| Gains on Business Disposals (d) | | 2 | |

| Loss on Assets Classified as Held for Sale (e) | | (236 | ) |

| Divestiture Costs (f) | | (10 | ) |

| Strategic Initiative Costs (g) | | (9 | ) |

| Regulatory Costs (h) | | (34 | ) |

| Other (k) | | (6 | ) |

| Income Before Taxes from Continuing Operations | $ | (134 | ) |

| Segment Adjusted Operating EBITDA Margin | |

| Taste | 18.6 | % |

| Health & Biosciences | 24.0 | % |

| Scent | 20.2 | % |

| Consolidated | 20.8 | % |

| | Three Months Ended September 30, 2025 |

| | Taste | | Health & Biosciences | | Scent | | Total |

| Net Sales | $ | 658 | | | $ | 559 | | | $ | 652 | | | $ | 1,869 |

| Cost of Sales | | (399 | ) | | | (299 | ) | | | (372 | ) | | |

| Research & Development Expenses | | (41 | ) | | | (57 | ) | | | (64 | ) | | |

| Selling & Administrative Expenses | | (112 | ) | | | (101 | ) | | | (107 | ) | | |

| Depreciation Expense Add-back (a) | | 17 | | | | 32 | | | | 18 | | | |

| Adjusted Operating EBITDA | $ | 123 | | | $ | 134 | | | $ | 127 | | | $ | 384 |

| Reconciliation of Adjusted Operating EBITDA: | |

| Total Adjusted Operating EBITDA | $ | 384 | |

| Depreciation & Amortization | | (151 | ) |

| Interest Expense | | (48 | ) |

| Other Expense, net | | (13 | ) |

| Restructuring and Other Charges (b) | | (14 | ) |

| Divestiture Costs (f) | | (11 | ) |

| Strategic Initiative Costs (g) | | (10 | ) |

| Regulatory Costs (h) | | (7 | ) |

| Income Before Taxes from Continuing Operations | $ | 130 | |

| Segment Adjusted Operating EBITDA Margin | |

| Taste | 18.7 | % |

| Health & Biosciences | 24.0 | % |

| Scent | 19.5 | % |

| Consolidated | 20.5 | % |

| | Nine Months Ended September 30, 2026 |

| | Taste | | Health & Biosciences | | Scent | | Total |

| Net Sales | $ | 2,055 | | | $ | 1,742 | | | $ | 2,005 | | | $ | 5,802 |

| Cost of Sales | | (1,227 | ) | | | (927 | ) | | | (1,141 | ) | | |

| Research & Development Expenses | | (139 | ) | | | (167 | ) | | | (187 | ) | | |

| Selling & Administrative Expenses | | (344 | ) | | | (324 | ) | | | (321 | ) | | |

| Depreciation Expense Add-back (a) | | 59 | | | | 102 | | | | 58 | | | |

| Adjusted Operating EBITDA | $ | 404 | | | $ | 426 | | | $ | 414 | | | $ | 1,244 |

| Reconciliation of Adjusted Operating EBITDA | |

| Total Adjusted Operating EBITDA | $ | 1,244 | |

| Depreciation & Amortization | | (462 | ) |

| Interest Expense | | (136 | ) |

| Other Expense, net | | (47 | ) |

| Restructuring and Other Charges (b) | | (15 | ) |

| Impairment of Goodwill (c) | | (23 | ) |

| Gains on Business Disposals (d) | | 1 | |

| Loss on Assets Classified as Held for Sale (e) | | (263 | ) |

| Divestiture Costs (f) | | (25 | ) |

| Strategic Initiative Costs (g) | | (27 | ) |

| Regulatory Costs (h) | | (115 | ) |

| Entity Realignment Costs (j) | | (2 | ) |

| Other (k) | | (4 | ) |

| Income Before Taxes from Continuing Operations | $ | 126 | |

| Segment Adjusted Operating EBITDA Margin | |

| Taste | 19.7 | % |

| Health & Biosciences | 24.5 | % |

| Scent | 20.6 | % |

| Consolidated | 21.4 | % |

| | Nine Months Ended September 30, 2025 |

| | Taste | | Health & Biosciences | | Scent | | Pharma Solutions | | Total |

| Net Sales | $ | 1,962 | | | $ | 1,638 | | | $ | 1,869 | | | $ | 369 | | | $ | 5,838 |

| Cost of Sales | | (1,190 | ) | | | (875 | ) | | | (1,051 | ) | | | (248 | ) | | |

| Research & Development Expenses | | (131 | ) | | | (163 | ) | | | (184 | ) | | | (8 | ) | | |

| Selling & Administrative Expenses | | (321 | ) | | | (294 | ) | | | (298 | ) | | | (42 | ) | | |

| Depreciation Expense Add-back (a) | | 49 | | | | 90 | | | | 50 | | | | 5 | | | |

| Adjusted Operating EBITDA | $ | 369 | | | $ | 396 | | | $ | 386 | | | $ | 76 | | | $ | 1,227 |

| Reconciliation of Adjusted Operating EBITDA: | |

| Total Adjusted Operating EBITDA | $ | 1,227 | |

| Depreciation & Amortization | | (439 | ) |

| Interest Expense | | (180 | ) |

| Other Expense, net | | (52 | ) |

| Restructuring and Other Charges (b) | | (49 | ) |

| Impairment of Goodwill (c) | | (34 | ) |

| Losses on Business Disposals (d) | | (111 | ) |

| Divestiture Costs (f) | | (88 | ) |

| Strategic Initiative Costs (g) | | (24 | ) |

| Regulatory Costs (h) | | (71 | ) |

| Gain on Debt Extinguishment (i) | | 488 | |

| Entity Realignment Costs (j) | | (5 | ) |

| Other (k) | | (6 | ) |

| Income Before Taxes from Continuing Operations | $ | 656 | |

| Segment Adjusted Operating EBITDA Margin | |

| Taste | 18.8 | % |

| Health & Biosciences | 24.2 | % |

| Scent | 20.7 | % |

| Pharma Solutions | 20.6 | % |

| Consolidated | 21.0 | % |

| (a) | | There is depreciation recorded within cost of sales, research & development expenses, and selling & administrative expenses, which is then added back to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results. |

| (b) | | For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program. |

| (c) | | For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group. For 2025, represents the impairment of goodwill attributable to the portion of the Food Ingredients reporting unit that is not included within the Food Ingredients or SCL disposal groups. |

| (d) | | For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized on the sale of the Nitrocellulose business. |

| (e) | | For 2026, represents the loss on assets classified as held for sale related to the Botanicals & Food Enhancements disposal group and the CitraSource business. |

| (f) | | For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. |

| (g) | | Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization. |

| (h) | | For 2026 and 2025, represents costs primarily related to provisions recognized for the ongoing investigations of the fragrance businesses and legal fees incurred. |

| (i) | | For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of the tender offers. |

| (j) | | For 2026 and 2025, primarily represents consulting costs related to the Company’s implementation of a phased restructuring initiative aimed at optimizing its legal entity framework. |

| (k) | | For 2026 and 2025, primarily represents the net impact of costs related to severance for certain executives who have separated from the Company. For 2026, also represents losses recognized upon the sale of fixed assets. |

International Flavors & Fragrances Inc.GAAP to Non-GAAP Reconciliation(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the three months ended September 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

| Reconciliation of Selling and Administrative Expenses1 |

| | Third Quarter |

| (DOLLARS IN MILLIONS) | | 2026 | | | | 2025 | |

| Reported (GAAP) | $ | 387 | | | $ | 348 | |

| Divestiture Costs (c) | | (10 | ) | | | (11 | ) |

| Strategic Initiatives Costs (f) | | (9 | ) | | | (9 | ) |

| Regulatory Costs (g) | | (34 | ) | | | (6 | ) |

| Other (i) | | (3 | ) | | | (2 | ) |

| Adjusted (Non-GAAP) | $ | 331 | | | $ | 320 | |

International Flavors & Fragrances Inc.GAAP to Non-GAAP Reconciliation(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| Reconciliation of Net Income (Loss) and EPS from Continuing Operations1 |

| | Third Quarter |

| | 2026 | | 2025 |

| (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) | Income before taxes | | (Benefit) Provision for income taxes (j) | | Net income attributable to IFF | | Diluted EPS | | Income before taxes | | (Benefit) Provision for income taxes (j) | | Net income attributable to IFF | | Diluted EPS |

| Reported (GAAP) | $ | (134 | ) | | $ | (7 | ) | | $ | (127 | ) | | $ | (0.50 | ) | | $ | 130 | | $ | 31 | | | $ | 99 | | | $ | 0.39 |

| Restructuring and Other Charges (a) | | 5 | | | | 1 | | | | 4 | | | | 0.01 | | | | 14 | | | 3 | | | | 11 | | | | 0.04 |

| Impairment of goodwill (b) | | 23 | | | | — | | | | 23 | | | | 0.09 | | | | — | | | — | | | | — | | | | — |

| Divestiture Costs (c) | | 10 | | | | 3 | | | | 7 | | | | 0.02 | | | | 11 | | | 3 | | | | 8 | | | | 0.03 |

| Gains on Business Disposals (d) | | (2 | ) | | | (1 | ) | | | (1 | ) | | | — | | | | — | | | (1 | ) | | | 1 | | | | — |

| Losses on Assets Classified as Held for Sale (e) | | 236 | | | | 48 | | | | 188 | | | | 0.73 | | | | — | | | — | | | | — | | | | — |

| Strategic Initiative Costs (f) | | 9 | | | | 2 | | | | 7 | | | | 0.03 | | | | 10 | | | 2 | | | | 8 | | | | 0.03 |

| Regulatory Costs (g) | | 34 | | | | 1 | | | | 33 | | | | 0.13 | | | | 7 | | | 2 | | | | 5 | | | | 0.02 |

| Entity Realignment Costs (h) | | — | | | | (12 | ) | | | 12 | | | | 0.05 | | | | — | | | — | | | | — | | | | — |

| Other (i) | | 6 | | | | — | | | | 6 | | | | 0.02 | | | | — | | | 1 | | | | (1 | ) | | | — |

| Adjusted (Non-GAAP) | $ | 187 | | | $ | 35 | | | $ | 152 | | | $ | 0.58 | | | $ | 172 | | $ | 41 | | | $ | 131 | | | $ | 0.51 |

| Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization1 |

| | Third Quarter |

| (DOLLARS AND SHARE AMOUNTS IN MILLIONS) | 2026 | | 2025 |

| Numerator | | | |

| Adjusted (Non-GAAP) Net Income | $ | 152 | | $ | 131 |

| Amortization of Acquisition related Intangible Assets | | 78 | | | 84 |

| Tax impact on Amortization of Acquisition related Intangible Assets (j) | | 19 | | | 20 |

| Amortization of Acquisition related Intangible Assets, net of tax (k) | | 59 | | | 64 |

| Adjusted (Non-GAAP) Net Income ex. Amortization | $ | 211 | | $ | 195 |

| | | | |

| Denominator | | | |

| Weighted average shares assuming dilution (diluted) | | 254 | | | 257 |

| Adjusted (Non-GAAP) EPS ex. Amortization | $ | 0.83 | | $ | 0.76 |

| (a) | | For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program. |

| (b) | | For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group. |

| (c) | | For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. |

| (d) | | For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business. |

| (e) | | For 2026, represents the loss on assets classified as held for sale related to the Botanicals & Food Enhancements disposal group. |

| (f) | | Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization. |

| (g) | | For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. |

| (h) | | In 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework and recognized a one-time tax benefit. In 2026, the Company updated the tax benefit previously recorded. |

| (i) | | For 2026, represents the net impact of costs related to severance for certain executives who have separated from the Company, and losses recognized upon the sale of fixed assets. |

| (j) | | The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments. |

| (k) | | Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |

International Flavors & Fragrances Inc.GAAP to Non-GAAP Reconciliation(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

For the nine months ended September 30, 2026 and 2025, there was no difference between Reported (GAAP) and Adjusted (Non-GAAP) gross profit.

| Reconciliation of Selling and Administrative Expenses1 |

| | Third Quarter Year-to-Date |

| (DOLLARS IN MILLIONS) | | 2026 | | | | 2025 | |

| Reported (GAAP) | $ | 1,158 | | | $ | 1,147 | |

| Divestiture Costs (c) | | (25 | ) | | | (88 | ) |

| Strategic Initiatives Costs (f) | | (27 | ) | | | (23 | ) |

| Regulatory Costs (g) | | (115 | ) | | | (70 | ) |

| Entity Realignment Costs (i) | | (2 | ) | | | (5 | ) |

| Other (j) | | (2 | ) | | | (6 | ) |

| Adjusted (Non-GAAP) | $ | 987 | | | $ | 955 | |

International Flavors & Fragrances Inc.GAAP to Non-GAAP Reconciliation(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| Reconciliation of Net Income (Loss) and EPS from Continuing Operations1 |

| | Third Quarter Year-to-Date |

| | 2026 | | 2025 |

| (DOLLARS IN MILLIONS EXCEPT PER SHARE AMOUNTS) | Income before taxes | | Provision (Benefit) for income taxes (k) | | Net income attributable to IFF (l) | | Diluted EPS | | Income before taxes | | Provision (Benefit) for income taxes (k) | | Net income attributable to IFF (l) | | Diluted EPS |

| Reported (GAAP) | $ | 126 | | | $ | 65 | | | $ | 60 | | $ | 0.23 | | $ | 656 | | | $ | (61 | ) | | $ | 716 | | | $ | 2.80 | |

| Restructuring and Other Charges (a) | | 15 | | | | 4 | | | | 11 | | | 0.04 | | | 49 | | | | 11 | | | | 38 | | | | 0.15 | |

| Impairment of Goodwill (b) | | 23 | | | | — | | | | 23 | | | 0.09 | | | 34 | | | | — | | | | 34 | | | | 0.13 | |

| Divestiture Costs (c) | | 25 | | | | 5 | | | | 20 | | | 0.08 | | | 88 | | | | 37 | | | | 51 | | | | 0.20 | |

| (Gains) losses on Business Disposals (d) | | (1 | ) | | | (1 | ) | | | — | | | — | | | 111 | | | | (138 | ) | | | 249 | | | | 0.97 | |

| Losses on Assets Classified as Held for Sale (e) | | 263 | | | | 52 | | | | 211 | | | 0.82 | | | — | | | | — | | | | — | | | | — | |

| Strategic Initiative Costs (f) | | 27 | | | | 6 | | | | 21 | | | 0.08 | | | 24 | | | | 5 | | | | 19 | | | | 0.07 | |

| Regulatory Costs (g) | | 115 | | | | 4 | | | | 111 | | | 0.43 | | | 71 | | | | 17 | | | | 54 | | | | 0.21 | |

| Gain on debt extinguishment (h) | | — | | | | — | | | | — | | | — | | | (488 | ) | | | (116 | ) | | | (372 | ) | | | (1.45 | ) |

| Entity Realignment Costs (i) | | 2 | | | | (11 | ) | | | 13 | | | 0.05 | | | 5 | | | | 361 | | | | (356 | ) | | | (1.40 | ) |

| Other (j) | | 4 | | | | — | | | | 4 | | | 0.02 | | | 6 | | | | 1 | | | | 5 | | | | 0.02 | |

| Adjusted (Non-GAAP) | $ | 599 | | | $ | 124 | | | $ | 474 | | $ | 1.84 | | $ | 556 | | | $ | 117 | | | $ | 438 | | | $ | 1.70 | |

| Reconciliation of Adjusted (Non-GAAP) EPS ex. Amortization1 |

| | Third Quarter Year-to-Date |

| (DOLLARS AND SHARE AMOUNTS IN MILLIONS) | 2026 | | 2025 |

| Numerator | | | |

| Adjusted (Non-GAAP) Net Income | $ | 474 | | $ | 438 |

| Amortization of Acquisition related Intangible Assets | | 244 | | | 246 |

| Tax impact on Amortization of Acquisition related Intangible Assets (k) | | 60 | | | 60 |

| Amortization of Acquisition related Intangible Assets, net of tax (m) | | 184 | | | 186 |

| Adjusted (Non-GAAP) Net Income ex. Amortization | $ | 658 | | $ | 624 |

| | | | |

| Denominator | | | |

| Weighted average shares assuming dilution (diluted) | | 255 | | | 255 |

| Adjusted (Non-GAAP) EPS ex. Amortization | $ | 2.58 | | $ | 2.45 |

| (a) | | For 2026 and 2025, represents costs primarily related to severance as part of the IFF Productivity Program. |

| (b) | | For 2026, represents the impairment of goodwill attributable to the Botanicals & Food Enhancements disposal group. For 2025, represents the impairment of goodwill related to the Food Ingredients reporting unit that is not included in the Food Ingredients or SCL disposal groups. |

| (c) | | For 2026 and 2025, primarily represents costs related to the Company’s completed and anticipated divestitures, excluding external costs related to the planned divestiture of the Food Ingredients disposal group and the completed divestiture of the SCL disposal group. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. |

| (d) | | For 2026, primarily represents gains recognized as part of final settlement adjustments related to the divestiture of the Nitrocellulose business in 2025. For 2025, primarily represents losses recognized as part of the sale of the Pharma Solutions disposal group, offset in part by gains recognized as part of the sale of the Nitrocellulose business. |

| (e) | | For 2026, represents the loss on assets classified as held for sale related to the CitraSource business and the Botanicals & Food Enhancements disposal group. |

| (f) | | Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Business Services (GBS) Centers. In 2026, the GBS reorganization has been expanded to include additional functions such as customer service, supply chain and logistics in addition to human resources, accounting and finance, as well as additional efforts to automate processes and expand the use of artificial intelligence (AI) for these functions. These costs primarily consisted of external consulting fees and salaries of individuals who are fully dedicated to such efforts. Costs to develop software and AI are only included to the extent that they do not qualify for capitalization. |

| (g) | | For 2026 and 2025, represents costs primarily related to legal fees incurred and provisions recognized for the ongoing investigations of the fragrance businesses. |

| (h) | | For 2025, represents the gain recognized on the extinguishment of debt in connection with the completion of the tender offers. |

| (i) | | In 2025, the Company implemented a phased restructuring initiative aimed at optimizing its legal entity framework and recognized a one-time tax benefit. In 2026, the Company updated the tax benefit previously recorded. |

| (j) | | For 2026 and 2025, primarily represents the net impact of costs related to severance for certain executives who have separated from the Company. For 2026, also represents losses recognized upon the sale of fixed assets. |

| (k) | | The income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for the relevant jurisdiction, except for those items which are non-taxable or subject to valuation allowances for which the tax expense (benefit) was calculated at 0%. The tax benefit for amortization is calculated in a similar manner as the tax effects of the non-GAAP adjustments. |

| (l) | | For each of the nine months ended September 30, 2026 and September 30, 2025, reported and adjusted net income from continuing operations are each decreased by income attributable to non-controlling interest from continuing operations of $1 million. |

| (m) | | Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax. |

International Flavors & Fragrances Inc.Debt Covenants(Amounts in millions)****(Unaudited)

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| Reconciliation of Credit Adjusted EBITDA to Net Income(1) |

| (DOLLARS IN MILLIONS) | Twelve Months Ended September 30, 2026 |

| Net income | $ | 183 |

| Interest expense | | 185 |

| Income taxes | | 107 |

| Depreciation and amortization | | 851 |

| Specified items(2) | | 420 |

| Non-cash items(3) | | 357 |

| Credit Adjusted EBITDA | $ | 2,103 |

| _______________________ |

| (1) | | Credit Adjusted EBITDA presented includes results from continuing and discontinued operations. |

| (2) | | Specified items consisted of restructuring and other charges, impairment of goodwill, divestiture costs, strategic initiatives costs, regulatory costs, and other costs that are not related to recurring operations. |

| (3) | | Non-cash items consisted of losses (gains) on business disposals, loss on assets classified as held for sale, and stock-based compensation. |

| Reconciliation of Net Debt to Total Debt |

| (DOLLARS IN MILLIONS) | September 30, 2026 |

| Total debt(1) | $ | 6,307 |

| Adjustments: | |

| Cash and cash equivalents | | 519 |

| Net debt | $ | 5,788 |

| _______________________ |

| (1) | | Total debt used for the calculation of net debt consisted of short-term debt, long-term debt, short-term finance lease obligations and long-term finance lease obligations. |

International Flavors & Fragrances Inc.Comparable Currency Neutral Segment Performance(Amounts in millions)****(Unaudited)

The following information and schedule provides reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedule is not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

| | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net Sales | | | | | | | |

| Taste(1) | $ | 691 | | | $ | 654 | | | $ | 2,028 | | | $ | 1,948 | |

| Health & Biosciences | | 566 | | | | 559 | | | | 1,700 | | | | 1,638 | |

| Scent(2) | | 691 | | | | 650 | | | | 1,963 | | | | 1,867 | |

| Pharma Solutions(3) | | — | | | | — | | | | — | | | | — | |

| Consolidated | $ | 1,948 | | | $ | 1,863 | | | $ | 5,691 | | | $ | 5,453 | |

| Segment Adjusted Operating EBITDA(6) | | | | | | | |

| Taste(1) | $ | 130 | | | $ | 122 | | | $ | 398 | | | $ | 358 | |

| Health & Biosciences | | 136 | | | | 134 | | | | 413 | | | | 390 | |

| Scent(2) | | 138 | | | | 125 | | | | 396 | | | | 378 | |

| Pharma Solutions(3) | | — | | | | — | | | | — | | | | — | |

| Total | | 404 | | | | 381 | | | | 1,207 | | | | 1,126 | |

| Depreciation & Amortization | | (156 | ) | | | (151 | ) | | | (462 | ) | | | (439 | ) |

| Interest Expense | | (46 | ) | | | (48 | ) | | | (136 | ) | | | (180 | ) |

| Other Expense, net | | (14 | ) | | | (13 | ) | | | (47 | ) | | | (52 | ) |

| Restructuring and Other Charges | | (5 | ) | | | (14 | ) | | | (15 | ) | | | (49 | ) |

| Impairment of Goodwill | | (23 | ) | | | — | | | | (23 | ) | | | (34 | ) |

| Gains (Losses) on Business Disposals | | 2 | | | | — | | | | 1 | | | | (111 | ) |

| Loss on Assets Classified as Held for Sale | | (236 | ) | | | — | | | | (263 | ) | | | — | |

| Divestiture Costs | | (10 | ) | | | (11 | ) | | | (25 | ) | | | (88 | ) |

| Strategic Initiative Costs | | (9 | ) | | | (10 | ) | | | (27 | ) | | | (24 | ) |

| Regulatory Costs | | (34 | ) | | | (7 | ) | | | (115 | ) | | | (71 | ) |

| Gain on Debt Extinguishment | | — | | | | — | | | | — | | | | 488 | |

| Entity Realignment Costs | | — | | | | — | | | | (2 | ) | | | (5 | ) |

| Other | | (6 | ) | | | — | | | | (4 | ) | | | (6 | ) |

| Impact of Currency Fluctuations(4) | | (1 | ) | | | — | | | | 37 | | | | — | |

| Impact of Business Divestitures(5) | | — | | | | 3 | | | | — | | | | 101 | |

| Income from continuing operations before taxes | $ | (134 | ) | | $ | 130 | | | $ | 126 | | | $ | 656 | |

| Segment Adjusted Operating EBITDA Margin(5) | | | | | | | |

| Taste | | 18.8 | % | | | 18.7 | % | | | 19.6 | % | | | 18.4 | % |

| Health & Biosciences | | 24.0 | % | | | 24.0 | % | | | 24.3 | % | | | 23.8 | % |

| Scent | | 20.0 | % | | | 19.2 | % | | | 20.2 | % | | | 20.2 | % |

| Consolidated | | 20.7 | % | | | 20.5 | % | | | 21.2 | % | | | 20.6 | % |

| ______________________ |

| (1) | | Taste sales and segment adjusted operating EBITDA information exclude the results of the Rene Laurent business that was divested on December 1, 2025, to present fully comparable scenarios. |

| (2) | | Scent sales and segment adjusted operating EBITDA information exclude the results of the CitraSource business that was divested on July 1, 2026, to present fully comparable scenarios. |

| (3) | | Pharma sales and segment adjusted operating EBITDA information exclude the results of the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios. |

| (4) | | Currency neutral sales are calculated by translating current year invoiced sale amounts at the exchange rates for the corresponding prior year period. |

| (5) | | Amounts exclude the results of the Rene Laurent business that was divested on December 1, 2025, the CitraSource business that was divested on July 1, 2026, and the Pharma Solutions disposal group and Nitrocellulose business that were divested on May 1, 2025 and May 9, 2025, respectively, to present fully comparable scenarios. |

| (6) | | Following the completed divestitures of the Pharma Solutions disposal group on May 1, 2025 and the Nitrocellulose business on May 9, 2025, the Company reallocated certain corporate costs previously attributed to the Pharma Solutions segment. These costs have been redistributed across the Taste, Health & Biosciences, and Scent segments to align with the updated 2025 operating model. |

| | | Nine Months Ended September 30, 2025 |

| | | Selling & Administrative Expenses | | Total EBITDA Impact |

| Taste | | $ | 6 | | $ | (6 | ) |

| Health & Biosciences | | | 6 | | | (6 | ) |

| Scent | | | 6 | | | (6 | ) |

| Total | | $ | 18 | | $ | (18 | ) |

| International Flavors & Fragrances Inc. |

| GAAP to Non-GAAP Reconciliation |

| Comparable Foreign Exchange Impact |

| (Unaudited) |

| |

| Q3 Taste | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 4% | | 4% | | (0.1)% |

| Portfolio Impact | | 1% | | 1% | | 0.0% |

| % Change - Comparable | | 5% | | 5% | | (0.1)% |

| Currency Impact | | 1% | | 2% | | 0.2% |

| % Change - Currency Neutral | | 6% | | 7% | | 0.1% |

| | | | | | | |

| Q3 Health & Biosciences | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 1% | | 1% | | 0.0% |

| Portfolio Impact | | 0% | | 1% | | 0.1% |

| % Change - Comparable | | 1% | | 2% | | 0.1% |

| Currency Impact | | 0% | | 0% | | 0.0% |

| % Change - Currency Neutral | | 1% | | 2% | | 0.1% |

| | | | | | | |

| Q3 Scent | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 6% | | 9% | | 0.7% |

| Portfolio Impact | | 0% | | 2% | | 0.3% |

| % Change - Comparable | | 6% | | 11% | | 1.0% |

| Currency Impact | | 0% | | (1)% | | (0.2)% |

| % Change - Currency Neutral | | 6% | | 10% | | 0.8% |

| | | | | | | |

| Q3 Consolidated | | Sales | | Adjusted Operating EBITDA | | Adjusted Operating EBITDA Margin |

| % Change - Reported | | 4% | | 5% | | 0.3% |

| Portfolio Impact | | 0% | | 1% | | 0.0% |

| % Change - Comparable | | 4% | | 6% | | 0.3% |

| Currency Impact | | 1% | | 0% | | (0.1)% |

| % Change - Currency Neutral | | 5% | | 6% | | 0.2% |

| _______________________ |

| Note: The sum of these items may not foot due to rounding. |

| International Flavors & Fragrances Inc. |

| GAAP to Non-GAAP Reconciliation |

| Comparable Foreign Exchange Impact |

| (Unaudited) |

| |

| YTD Taste | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 5% | | 9% | | 0.9% |

| Portfolio Impact | | 0% | | 4% | | 0.4% |

| % Change - Comparable | | 5% | | 13% | | 1.3% |

| Currency Impact | | (1)% | | (2)% | | (0.1)% |

| % Change - Currency Neutral | | 4% | | 11% | | 1.2% |

| | | | | | | |

| YTD Health & Biosciences | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 6% | | 8% | | 0.3% |

| Portfolio Impact | | 0% | | 1% | | 0.4% |

| % Change - Comparable | | 6% | | 9% | | 0.7% |

| Currency Impact | | (2)% | | (3)% | | (0.2)% |

| % Change - Currency Neutral | | 4% | | 6% | | 0.5% |

| | | | | | | |

| YTD Scent | | Sales | | Segment Adjusted Operating EBITDA | | Segment Adjusted Operating EBITDA Margin |

| % Change - Reported | | 7% | | 7% | | (0.1)% |

| Portfolio Impact | | 0% | | 3% | | 0.5% |

| % Change - Comparable | | 7% | | 10% | | 0.4% |

| Currency Impact | | (2)% | | (5)% | | (0.4)% |

| % Change - Currency Neutral | | 5% | | 5% | | 0.0% |

| | | | | | | |

| YTD Consolidated | | Sales | | Adjusted Operating EBITDA | | Adjusted Operating EBITDA Margin |

| % Change - Reported | | (1)% | | 1% | | 0.4% |

| Portfolio Impact | | 7% | | 9% | | 0.3% |

| % Change - Comparable | | 6% | | 10% | | 0.7% |

| Currency Impact | | (2)% | | (3)% | | (0.2)% |

| % Change - Currency Neutral | | 4% | | 7% | | 0.5% |

| _______________________ |

| Note: The sum of these items may not foot due to rounding. |

View source version on businesswire.com: https://www.businesswire.com/news/home/20261103127754/en/

Media Relations: Jennifer McGowan 848.358.1680 [email protected]

Investor Relations: Michael Bender 212.708.7263 [email protected]

Source: IFF

Prompts

International Flavors & Fragrances, Inc. (ticker IFF), listed in United States.

ETFs Holding International Flavors & Fragrances, Inc.

ETF Weight in ETF Shares Market value As of
FPAG 3.64% 247,861 $ 19.636M Jun 30, 2026
BSMC 2.70% 56,755 $ 4.496M Jun 30, 2026
AMID 1.92% 28,131 $ 2.23M Nov 18, 2026
CSTK 1.65% 36,694 $ 2.907M Jul 31, 2026
BUSA 1.39% 52,409 $ 4.152M Jun 30, 2026
DVND 1.36% 9,072 $ 718.684K Jun 30, 2026
MMID 1.17% 4,926 $ 425.262K Aug 31, 2026
FEGE 0.90% 262,291 $ 22.644M Aug 31, 2026
ABCS 0.67% 974 $ 84.085K Aug 31, 2026
LCF 0.62% 5,051 $ 400.14K Jun 30, 2026
PAPI 0.58% 29,198 $ 2.313M Jun 30, 2026
FEMV 0.57% 384 $ 30.42K Jun 30, 2026
SMIZ 0.48% 15,246 $ 1.316M Aug 31, 2026
RCGE 0.45% 5,552 $ 440K Nov 18, 2026
CDX 0.22% 6,914.0267 $ 549.181K Nov 17, 2026
AVMC 0.20% 14,121 $ 1.13M Nov 16, 2026
CLSE short -0.18% -18,760 $ -1.62M Aug 31, 2026
FMDE 0.16% 145,198 $ 11.503M Jun 30, 2026
FTQI 0.13% 15,652 $ 1.252M Nov 16, 2026
PEPS 0.13% 472 $ 37.392K Jun 30, 2026
VFVA 0.12% 13,703 $ 1.183M Aug 31, 2026
JFLI 0.09% 531 $ 42.177K Nov 17, 2026
SPIN 0.09% 497 $ 39.755K Nov 16, 2026
MODL 0.09% 11,454 $ 907.386K Jun 30, 2026
LGDX 0.08% 1,379 $ 110.306K Nov 17, 2026
DFUV 0.07% 136,944 $ 11.008M Nov 12, 2026
DFSU 0.07% 19,935 $ 1.602M Nov 12, 2026
DXUV 0.06% 49,458 $ 3.975M Nov 12, 2026
IALT short -0.06% -63,990 $ -5.119M Nov 16, 2026
AAUS 0.06% 3,701 $ 290K Nov 18, 2026
DFAC 0.05% 550,034 $ 44.212M Nov 12, 2026
APUE 0.05% 14,365 $ 1.24M Aug 31, 2026
DFLV 0.05% 45,382 $ 3.648M Nov 12, 2026
XMAG 0.04% 1,204 $ 96.778K Nov 13, 2026
AVLC 0.04% 7,197 $ 575.688K Nov 16, 2026
DCOR 0.04% 214,351 $ 17.23M Nov 12, 2026
DFAU 0.04% 58,942 $ 4.738M Nov 12, 2026
NTSD 0.04% 159 $ 12.596K Jun 30, 2026
AVSU 0.03% 1,893 $ 151.421K Nov 16, 2026
DFUS 0.03% 77,165 $ 6.203M Nov 12, 2026
GDE 0.03% 1,594 $ 137.61K Aug 31, 2026
HCMT 0.02% 1,777 $ 140.774K Jul 31, 2026
EBI 0.02% 1,995 $ 172.228K Aug 31, 2026
VOXP 0.02% 15 $ 1,188.30 Jul 31, 2026
AVUS 0.02% 42,650 $ 3.412M Nov 16, 2026
NTSX 0.01% 2,271 $ 179.909K Jun 30, 2026
ACVF 0.01% 227 $ 17.983K Jul 31, 2026
CSHP 0.01% 385 $ 30.796K Nov 16, 2026
GSPY 0.01% 783 $ 62.632K Nov 17, 2026
FEAC 0.00% 3 $ 237.66 Jun 30, 2026
CORO 0.00% 161 $ 12.873K Nov 16, 2026